A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

被引：2
|
作者：
Sun, Mingyuan [1 ]
Qi, Junyuan [1 ]
Chen, Zi [2 ]
Zhang, Hongli [2 ]
Song, Yongping [3 ]
Shen, Aizong [4 ]
Liu, Huilan [4 ]
Huang, Jianying [5 ]
Zhou, Fuling [5 ]
Jin, Jie [6 ]
Lu, Ming [7 ]
Ahmad, Mohammad [7 ]
Men, Lichuang [2 ]
Cen, Wan [2 ]
Yang, Dajun [2 ,8 ]
Wang, Jianxiang [1 ]
Zhai, Yifan [2 ,7 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[3] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] USTC Anhui Prov Hosp, Affiliated Hosp 1, Hefei, Peoples R China
[5] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[7] Ascentage Pharma Grp Inc, Rockville, MD USA
[8] Sun Yat Sen Univ, State Key Lab Oncol South China Collaborat Innova, Canc Ctr, Guangzhou, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152235
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3730
引用
收藏
页码：3730 / +
页数：4
相关论文
共 50 条
  • [21] Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (R/R Ph plus ALL): First Report from a Phase 1 Study
    Zhang, Jingliao
    Wang, Junxia
    Guo, Huanshan
    Liu, Tianfeng
    Zhang, Xiaoyan
    Zhang, Ranran
    Ruan, Min
    Chang, Lixian
    Liu, Xiaoming
    Ren, Yuanyuan
    Chen, Xia
    Wang, Hengbang
    Chen, Zi
    Zhang, Yingchi
    Chen, Yumei
    Zhang, Li
    Guo, Ye
    Liu, Fang
    Chen, Xiaojuan
    Zou, Yao
    Yang, Wenyu
    Zhai, Yifan
    Zhu, Xiaofan
    BLOOD, 2024, 144 : 1443 - 1444
  • [22] Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Alegria, Victoria R.
    Ahmed, Salman
    Laplant, Betsy
    Manna, Alak
    Parrondo, Ricardo
    Roy, Vivek
    Sher, Taimur
    Edwards, Brett
    Lanier, Stephanie
    Jackson, Keisha
    Chanan-Khan, Asher A.
    Paulus, Aneel
    BLOOD, 2019, 134
  • [23] Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
    Roberts, Andrew W.
    Advani, Ranjana H.
    Kahl, Brad S.
    Persky, Daniel
    Sweetenham, John W.
    Carney, Dennis A.
    Yang, Jianning
    Busman, Todd B.
    Enschede, Sari H.
    Humerickhouse, Roderick A.
    Seymour, John F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (05) : 669 - 678
  • [24] Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML
    Daver, Naval
    Pollyea, Daniel A.
    Yee, Karen W. L.
    Fenaux, Pierre
    Brandwein, Joseph M.
    Vey, Norbert
    Martinelli, Giovanni
    Kelly, Kevin R.
    Roboz, Gail J.
    Garcia, Jacqueline S.
    Pigneux, Arnaud
    Kshirsagar, Smita
    Dail, Monique
    Wang, Jue
    Mobasher, Mehrdad
    Chen, Lin-Chi
    Hong, Wan-Jen
    Konopleva, Marina
    Andreeff, Michael
    BLOOD, 2017, 130
  • [25] Phase I trial of interleukin-2 (IL-2) and rituximab in patients (pts) with relapsed or refractory B-cell lymphomas (R/R-BCL).
    Porcu, P
    Farag, S
    Marcucci, G
    Avalos, B
    Rhoades, C
    Fisher, B
    Byrd, JC
    Grever, MR
    Caligiuri, MA
    BLOOD, 2001, 98 (11) : 245B - 245B
  • [26] Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    Wilson, Wyndham H.
    Connor, Owen A. O.
    Czuczman, Myron S.
    LaCasce, Ann S.
    Gerecitano, John F.
    Leonard, John P.
    Tulpule, Anil
    Dunleavy, Kieron
    Xiong, Hao
    Chiu, Yi Lin
    Cui, Yue
    Busman, Todd
    Elmore, Steven W.
    Rosenberg, Saul H.
    Krivoshik, Andrew P.
    Enschede, Sari H.
    Humerickhouse, Rod A.
    LANCET ONCOLOGY, 2010, 11 (12): : 1149 - 1159
  • [27] Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study
    Daver, Naval G.
    Pollyea, Daniel A.
    Garcia, Jacqueline S.
    Jonas, Brian A.
    Yee, Karen W. L.
    Fenaux, Pierre
    Assouline, Sarit
    Vey, Norbert
    Olin, Rebecca
    Roboz, Gail J.
    Tafuri, Agostino
    Visani, Giuseppe
    Kirschbrown, Whitney
    Green, Cherie
    Ma, Connie
    Dail, Monique
    Wang, Jue
    Ott, Marion G.
    Mobasher, Mehrdad
    Phuong, Patrick
    Hong, Wan-Jen
    Konopleva, Marina Y.
    Andreeff, Michael
    BLOOD, 2018, 132
  • [28] A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.
    Rutkowski, Piotr
    Kowalski, Dariusz
    Moreno, Victor
    Calvo, Aitana
    Thistlethwaite, Fiona
    Plummer, Elizabeth Ruth
    Han, Kevin Tianxiang
    Loffredo, John
    Carcione, Jenna
    Jonathan, Daniel
    Philip, Vinod
    Baig, Mahadi
    Hellemans, Peter
    Bulat, Iurie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors
    Kalinsky, Kevin
    Tolcher, Anthony W.
    Wang, Shushen
    Meric-Bernstam, Funda
    Winkler, Robert
    Li, Mingyu
    Sun, Xuemei
    Pan, Wentao
    Paudyal, Bishnuhari
    Liang, Zhiyan
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
    Izutsu, Koji
    Yamamoto, Kazuhito
    Kato, Koji
    Ishikawa, Takayuki
    Fukuhara, Noriko
    Terui, Yasuhito
    Choi, Ilseung
    Humphrey, Kathryn
    Kim, Su Young
    Okubo, Sumiko
    Ogawa, Natsumi
    Nishimura, Yasuko
    Salem, Ahmed Hamed
    Maruyama, Dai
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
12345